Federated Investors Inc Decreased Corcept Therapeutics Inc (NASDAQ:CORT) Stake By $11.50 Million

August 12, 2018 - By Sheila Anderson

Corcept Therapeutics Incorporated (NASDAQ:CORT) LogoInvestors sentiment decreased to 1.28 in 2018 Q1. Its down 0.21, from 1.49 in 2017Q4. It dropped, as 28 investors sold CORT shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported. Wells Fargo And Commerce Mn holds 0% or 524,900 shares. Texas Permanent School Fund has 63,095 shares. Parametric Port Ltd Company holds 199,745 shares or 0% of its portfolio. Riverhead Limited Company owns 9,400 shares for 0.01% of their portfolio. Blair William Il has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Tci Wealth Advsr holds 123 shares or 0% of its portfolio. Mason Street Advsrs Ltd holds 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 26,440 shares. Hillsdale Inv Management stated it has 0.18% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Gsa Partners Limited Liability Partnership invested in 192,182 shares. State Of Wisconsin Board owns 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 92,000 shares. Moreover, Crow Point Ptnrs Ltd Co has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Arrowstreet Capital L P holds 0.03% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 836,280 shares. Piedmont Investment Advisors Limited Co invested in 0.01% or 20,371 shares. Envestnet Asset Inc holds 0% or 13,054 shares in its portfolio. California State Teachers Retirement has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Since March 6, 2018, it had 1 insider buy, and 6 selling transactions for $988,257 activity. FISHMAN ROBERT S sold $125,323 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, March 7. $155,102 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was bought by GALA RENEE D.

Federated Investors Inc decreased its stake in Corcept Therapeutics Inc (NASDAQ:CORT) by 6.04% based on its latest 2018Q2 regulatory filing with the SEC. Federated Investors Inc sold 766,619 shares as the company’s stock rose 20.10% while stock markets declined. The institutional investor held 11.92 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $187.38 million, down from 12.69M at the end of the previous reported quarter. Federated Investors Inc who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $1.53B market cap company. The stock decreased 5.15% or $0.72 during the last trading session, reaching $13.26. About 4.15M shares traded or 227.23% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since August 13, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Federated Investors Inc, which manages about $34.12 billion US Long portfolio, upped its stake in Veeva Sys Inc (NYSE:VEEV) by 155,953 shares to 4.02 million shares, valued at $309.16 million in 2018Q2, according to the filing. It also increased its holding in Pepsico Inc (NYSE:PEP) by 629,143 shares in the quarter, for a total of 2.27 million shares, and has risen its stake in Rexnord Corp New (NYSE:RXN).

Federated Investors Inc is a Pennsylvania-based institutional investor with more than $254.00 billion AUM in March, 2014. This fund invests only a small percentage of its assets in equities and options. Federated Investors Inc is the 12th largest institutional investor in our database. Taken from Federated Investors latest Adv, the fund reported to have 93 full and part-time employees. Among which 91 performing investment advisory and research functions. The institutional investor had more than 107 clients.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics Inc (NASDAQ:CORT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Corcept Therapeutics Inc had 7 analyst reports since March 8, 2018 according to SRatingsIntel. FBR Capital maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Tuesday, June 12 with “Buy” rating. The firm has “Buy” rating given on Tuesday, June 19 by FBR Capital. The firm earned “Buy” rating on Thursday, March 8 by FBR Capital. Seaport Global initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, April 13 with “Buy” rating. Stifel Nicolaus downgraded Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, May 31 to “Hold” rating. FBR Capital maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Tuesday, March 20 with “Buy” rating.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.53 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 11.73 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Benzinga.com which released: “7 Stocks Moving In Thursday’s After-Hours Session” on August 09, 2018, also Seekingalpha.com with their article: “Should You Buy Corcept Therapeutics Before Earnings?” published on July 23, 2018, Benzinga.com published: “60 Stocks Moving In Friday’s Mid-Day Session” on August 10, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Gurufocus.com and their article: “3 Stocks to Sell Friday” published on August 10, 2018 as well as Streetinsider.com‘s news article titled: “After-Hours Stock Movers 08/09: (TTD) (OSTK) (PBYI) Higher; (CORT) (XONE) (DBX) Lower (more…)” with publication date: August 09, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.